Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials

H Wiend, R Hohlfeld - BioDrugs, 2002 - Springer
The therapy for multiple sclerosis (MS) has changed dramatically over the past decade.
Recent immunobiological findings and current pathophysiological concepts together with …

Extracorporeal photopheresis: past, present, and future

R Knobler, ML Barr, DR Couriel, JLM Ferrara… - Journal of the American …, 2009 - Elsevier
Extracorporeal photopheresis (ECP) is a leukapheresis-based therapy that uses 8-
methoxypsoralen and ultraviolet A irradiation. Used alone or in combination with biological …

Evidence‐based practice of photopheresis 1987–2001: a report of a workshop of the British Photodermatology Group and the UK Skin Lymphoma Group

KE McKenna, S Whittaker, LE Rhodes, P Taylor… - 2006 - academic.oup.com
Photopheresis or extracorporeal photochemotherapy (ECP) is a novel immunomodulatory
therapy which involves separation of the patient's leucocyte‐rich plasma, followed by ex vivo …

[图书][B] Autoimmune diseases of the skin

M Hertl - 2001 - Springer
Product liability: The publisher can give no guarantee for all the information contained in this
book. This does also refer to information about drug dosage and application thereof. In every …

Extracorporeal photopheresis: a review

A Oliven, Y Shechter - Blood reviews, 2001 - Elsevier
Extracorporeal phototherapy (ECP) is a therapeutic approach based on the biological effect
of psoralen 8-methoxypsoralen (8-MOP) and ultraviolet light A (UVA) on mononuclear cells …

Recent advances in phototherapy

JC Simon, D Pfieger, E Schöpf - European Journal of Dermatology, 2000 - jle.com
This synopsis reviews recent developments in dermatological phototherapy. UVA1
phototherapy (340-400 nm) is effective in the treatment of inflammatory skin diseases such …

Extracorporeal photopheresis: how, when, and why

DM Ward - Journal of clinical apheresis, 2011 - Wiley Online Library
Extracorporeal photopheresis (ECP) is a well‐tolerated procedure that suppresses T‐
lymphocyte activity in a clonally‐specific way. It is an effective therapy that has established …

Management of severe scleroderma with long-term extracorporeal photopheresis

K Krasagakis, E Dippel, J Ramaker, M Owsianowski… - Dermatology, 1998 - karger.com
Background: The management of systemic sclerosis remains unsatisfactory. Thus far, the
action of extracorporeal photopheresis (ECP) in severe systemic scleroderma has been …

Extracorporeal photopheresis for systemic sclerosis: A meta‐analysis of randomized clinical trials

C Delbrück, T Gambichler, L Susok… - Dermatologic …, 2022 - Wiley Online Library
Abstract Systemic sclerosis (scleroderma)(SSc) is a rare autoimmune disorder characterized
by excessive production of collagen. Extracorporeal photopheresis (photochemotherapy …

Furanocoumarins: Biomolecules of therapeutic interest

JA Del Río, L Díaz, D García-Bernal, M Blanquer… - Studies in Natural …, 2014 - Elsevier
Furanocoumarins are a subgroup of phenolic compounds included in the coumarins group.
They can be subdivided into two types: linear, generically known as psoralens, among …